New combo therapy aims to turn inoperable liver cancer into surgical candidates
NCT ID NCT07012798
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a sequence of treatments—chemotherapy infused into the liver, two drugs (durvalumab and bevacizumab), and targeted radiation—can shrink advanced liver cancer enough to allow surgery. About 30 adults with liver cancer that cannot currently be removed will receive this combination. The goal is to see if the cancer becomes operable and to monitor side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Cancer Hospital Airport Hospital
RECRUITINGTianjin, Tianjin Municipality, 300308, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a 'No-Touch' microwave technique match surgery for liver tumors?
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- AI-Powered surveillance may outsmart liver cancer recurrence
- Blood markers may forecast liver cancer treatment success
- Can a diabetes drug help fight liver cancer? a trial puts it to the test
- Can a triple therapy shrink untreatable liver tumors?